Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Purinergic Signal ; 17(2): 229-240, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-33751327

RESUMO

Adenosine triphosphate (ATP) and its metabolites adenosine diphosphate, adenosine monophosphate, and adenosine in purinergic signaling pathway play important roles in many diseases. Activation of P2 receptors (P2R) channels and subsequent membrane depolarization can induce accumulation of extracellular ATP, and furtherly cause kinds of diseases, such as pain- and immune-related diseases, cardiac dysfunction, and tumorigenesis. Active ingredients of traditional Chinese herbals which exhibit superior pharmacological activities on diversified P2R channels have been considered as an alternative strategy of disease treatment. Experimental evidence of potential ingredients in Chinese herbs targeting P2R and their pharmacological activities were outlined in the study.


Assuntos
Medicamentos de Ervas Chinesas/química , Medicamentos de Ervas Chinesas/uso terapêutico , Receptores Purinérgicos P2/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Trifosfato de Adenosina/metabolismo , Animais , Humanos , Agonistas do Receptor Purinérgico P2/uso terapêutico , Antagonistas do Receptor Purinérgico P2/uso terapêutico
2.
Int J Mol Sci ; 22(2)2021 Jan 16.
Artigo em Inglês | MEDLINE | ID: mdl-33467058

RESUMO

Vascular dysfunction in cardiovascular diseases includes vasomotor response impairments, endothelial cells (ECs) activation, and smooth muscle cells (SMCs) proliferation and migration to the intima. This results in intimal hyperplasia and vessel failure. We previously reported that activation of the P2Y11 receptor (P2Y11R) in human dendritic cells, cardiofibroblasts and cardiomyocytes was protective against hypoxia/reoxygenation (HR) lesions. In this study, we investigated the role of P2Y11R signaling in vascular dysfunction. P2Y11R activity was modulated using its pharmacological agonist NF546 and antagonist NF340. Rat aortic rings were exposed to angiotensin II (AngII) and evaluated for their vasomotor response. The P2Y11R agonist NF546 reduced AngII-induced vascular dysfunction by promoting EC-dependent vasorelaxation, through an increased nitric oxide (NO) bioavailability and reduced AngII-induced H2O2 release; these effects were prevented by the use of the P2Y11R antagonist NF340. Human vascular SMCs and ECs were subjected to AngII or H/R simulation in vitro. P2Y11R agonist modulated vasoactive factors in human ECs, that is, endothelial nitric oxide synthase (eNOS) and endothelin-1, reduced SMC proliferation and prevented the switch towards a synthetic phenotype. H/R and AngII increased ECs secretome-induced SMC proliferation, an effect prevented by P2Y11R activation. Thus, our data suggest that P2Y11R activation may protect blood vessels from HR-/AngII-induced injury and reduce vascular dysfunctions. These results open the way for new vasculoprotective interventions.


Assuntos
Difosfonatos/farmacologia , Naftalenossulfonatos/farmacologia , Agonistas do Receptor Purinérgico P2/farmacologia , Receptores Purinérgicos P2/metabolismo , Traumatismo por Reperfusão/metabolismo , Túnica Íntima/patologia , Angiotensina II/toxicidade , Animais , Aorta/efeitos dos fármacos , Aorta/metabolismo , Aorta/patologia , Aorta/fisiopatologia , Difosfonatos/uso terapêutico , Endotelina-1/metabolismo , Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/metabolismo , Humanos , Hiperplasia/prevenção & controle , Masculino , Miócitos de Músculo Liso/efeitos dos fármacos , Miócitos de Músculo Liso/metabolismo , Naftalenossulfonatos/uso terapêutico , Óxido Nítrico/metabolismo , Óxido Nítrico Sintase Tipo III/metabolismo , Agonistas do Receptor Purinérgico P2/uso terapêutico , Ratos , Ratos Wistar , Traumatismo por Reperfusão/tratamento farmacológico , Túnica Íntima/efeitos dos fármacos , Túnica Íntima/metabolismo , Vasodilatação , Água/metabolismo
3.
Invest Ophthalmol Vis Sci ; 60(1): 255-264, 2019 01 02.
Artigo em Inglês | MEDLINE | ID: mdl-30649152

RESUMO

Purpose: Exposure to airborne particulate matter can induce ocular surface damage and inflammation. We evaluated the effects of a topical mucin secretagogue on the mitigation of ocular surface damage induced by exposure to airborne carbon black (CB). Methods: Sprague-Dawley rats were exposed to ambient CB for 2 hours twice daily for 5 days. Corneal staining score and tear lactic dehydrogenase (LDH) activity were measured to evaluate ocular surface damage. Serum immunoglobulin (Ig) G and IgE levels and the sizes of cervical lymph nodes were also measured. The expressions of interleukin (IL)-4, IL-17, and interferon (IFN)-γ were measured by Western blot analysis. Diquafosol tetrasodium was instilled six times a day for 5 days, and the extent of ocular surface damage was evaluated. Results: After exposure to airborne CB, the median corneal staining score and LDH activity were significantly increased. Serum IgG and IgE levels and the sizes of cervical lymph nodes were also significantly increased. Additionally, the expression of IL-4 and IFN-γ was elevated in the anterior segment of the eyeball. Furthermore, the expression of IL-4, IL-17, and IFN-γ was elevated in the cervical lymph nodes. When exposed to airborne black carbon, topical diquafosol tetrasodium significantly increased tear MUC5AC concentration and decreased tear LDH activity. Conclusions: Exposure to airborne CB induced ocular surface damage and increased proinflammatory cytokines in the eyes and cervical lymph nodes. Topical mucin secretagogues seem to have a protective effect on the ocular surface against exposure to airborne particulate matters.


Assuntos
Doenças da Córnea/prevenção & controle , Reação a Corpo Estranho/prevenção & controle , Mucina-5AC/metabolismo , Material Particulado/efeitos adversos , Polifosfatos/uso terapêutico , Agonistas do Receptor Purinérgico P2/uso terapêutico , Secretagogos/metabolismo , Nucleotídeos de Uracila/uso terapêutico , Animais , Western Blotting , Doenças da Córnea/etiologia , Doenças da Córnea/metabolismo , Citocinas/metabolismo , Ensaio de Imunoadsorção Enzimática , Reação a Corpo Estranho/etiologia , Reação a Corpo Estranho/metabolismo , Imunoglobulina E/sangue , Imunoglobulina G/sangue , L-Lactato Desidrogenase/metabolismo , Linfonodos/metabolismo , Linfonodos/patologia , Masculino , Pescoço , Ratos , Ratos Sprague-Dawley , Fuligem/efeitos adversos , Lágrimas/enzimologia
4.
Arterioscler Thromb Vasc Biol ; 35(11): 2307-15, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26359511

RESUMO

Under various pathological conditions, including thrombosis and inflammation, extracellular nucleotide levels may increase because of both active release and passive leakage from damaged or dying cells. Once in the extracellular compartment, nucleotides interact with plasma membrane receptors belonging to the P2 purinergic family, which are expressed by virtually all circulating blood cells and in most blood vessels. In this review, we focus on the specific role of the 3 platelet P2 receptors P2Y1, P2Y12, and P2X1 in hemostasis and arterial thrombosis. Beyond platelets, these 3 receptors, along with the P2Y2, P2Y6, and P2X7 receptors, constitute the main P2 receptors mediating the proinflammatory effects of nucleotides, which play important roles in various functions of circulating blood cells and cells of the vessel wall. Each of these P2 receptor subtypes specifically contributes to chronic or acute vascular inflammation and related diseases, such as atherosclerosis, restenosis, endotoxemia, and sepsis. The potential for therapeutic targeting of these P2 receptor subtypes is also discussed.


Assuntos
Inflamação/metabolismo , Purinas/metabolismo , Receptores Purinérgicos P2/metabolismo , Trombose/metabolismo , Animais , Anti-Inflamatórios/uso terapêutico , Coagulação Sanguínea , Fibrinolíticos/uso terapêutico , Humanos , Inflamação/sangue , Inflamação/tratamento farmacológico , Mediadores da Inflamação/sangue , Agonistas do Receptor Purinérgico P2/uso terapêutico , Antagonistas do Receptor Purinérgico P2/uso terapêutico , Receptores Purinérgicos P2/efeitos dos fármacos , Receptores Purinérgicos P2X7/metabolismo , Receptores Purinérgicos P2Y2/metabolismo , Transdução de Sinais , Trombose/sangue , Trombose/tratamento farmacológico
5.
Int J Mol Sci ; 15(12): 23672-704, 2014 Dec 18.
Artigo em Inglês | MEDLINE | ID: mdl-25530618

RESUMO

Purinergic signalling plays a crucial role in proper functioning of the nervous system. Mechanisms depending on extracellular nucleotides and their P2 receptors also underlie a number of nervous system dysfunctions. This review aims to present the role of purinergic signalling, with particular focus devoted to role of P2 family receptors, in epilepsy, depression, neuropathic pain, nervous system neoplasms, such as glioma and neuroblastoma, neurodegenerative diseases like Parkinson's disease, Alzheimer's disease and multiple sclerosis. The above-mentioned conditions are associated with changes in expression of extracellular ectonucleotidases, P2X and P2Y receptors in neurons and glial cells, as well as releasing considerable amounts of nucleotides from activated or damaged nervous tissue cells into the extracellular space, which contributes to disturbance in purinergic signalling. The numerous studies indicate a potential possibility of using synthetic agonists/antagonists of P2 receptors in treatment of selected nervous system diseases. This is of particular significance, since numerous available agents reveal a low effectiveness and often produce side effects.


Assuntos
Doenças do Sistema Nervoso/metabolismo , Receptores Purinérgicos P2X/metabolismo , Receptores Purinérgicos P2Y/metabolismo , Animais , Humanos , Doenças do Sistema Nervoso/tratamento farmacológico , Doenças do Sistema Nervoso/genética , Agonistas do Receptor Purinérgico P2/farmacologia , Agonistas do Receptor Purinérgico P2/uso terapêutico , Antagonistas do Receptor Purinérgico P2/farmacologia , Antagonistas do Receptor Purinérgico P2/uso terapêutico , Receptores Purinérgicos P2X/química , Receptores Purinérgicos P2X/genética , Receptores Purinérgicos P2Y/química , Receptores Purinérgicos P2Y/genética
6.
Neuropharmacology ; 61(1-2): 25-34, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21338615

RESUMO

While the position of adenosine as an endogenous anticonvulsant is well established, it is unclear to what extent its precursor, ATP, contributes to seizure activity via P2 receptors. In this study we have addressed this issue through the use of ATP biosensors and agonists and antagonists of ATP P2 receptors to detect the release and role of ATP, respectively, during electrically-evoked electrographic seizure-like events (eSLEs) in rat hippocampal slices. The broad-spectrum P2 receptor antagonists RB-2 and PPADS (10µM) caused a small ∼30% inhibition of eSLE duration, and a reduction in intensity. This inhibition of eSLEs was partially reproduced with the P2X(1,2/3,3) antagonist NF023 (10µM), but not the P2X(7) antagonist BBG (10µM). However, the P2X receptor agonist α,ß-meATP did not enhance eSLEs, but instead reduced their duration. Furthermore, we could discern no role for P2Y(1) receptors in electrically-evoked eSLEs: both the P2Y(1) antagonist MRS2179 (10µM) and the P2Y(1) receptor agonist 2-methylthioADP (10µM) were without effect on eSLEs. Consistent with a minor role for ATP P2 receptors on eSLEs we could detect no ATP release during eSLEs, although appreciable quantities of adenosine were detected, which had a pronounced inhibitory action on eSLEs via A(1) receptors. We conclude that the role of ATP P2 receptors in modulating electrographic seizure activity is limited, at least in models such as this one requiring electrical stimulation of afferent fibres. We further conclude that the presence and action of adenosine under these conditions may primarily reflect direct release of this purine.


Assuntos
Técnicas Biossensoriais/métodos , Hipocampo/fisiopatologia , Agonistas do Receptor Purinérgico P2/farmacologia , Antagonistas do Receptor Purinérgico P2/farmacologia , Purinas/farmacologia , Receptores Purinérgicos P2/fisiologia , Convulsões/fisiopatologia , Animais , Estimulação Elétrica/efeitos adversos , Hipocampo/efeitos dos fármacos , Masculino , Técnicas de Cultura de Órgãos , Agonistas do Receptor Purinérgico P2/uso terapêutico , Antagonistas do Receptor Purinérgico P2/uso terapêutico , Purinas/uso terapêutico , Ratos , Ratos Sprague-Dawley , Convulsões/etiologia , Convulsões/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...